Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. [PDF]
PLoS ONE, 2016 The paper aimed to estimate the incremental cost-effectiveness ratio (ICER) at the public published price for delayed-release dimethyl fumarate versus relevant Multiple Sclerosis disease-modifying therapies available in France in June 2015.The economic ...
Julie Chevalier +3 more
doaj +1 more source
Drug-Repurposing Strategy for Dimethyl Fumarate
Pharmaceuticals, 2023 In the area of drug discovery, repurposing strategies represent an approach to discover new uses of approved drugs besides their original indications.
Salvatore Giunta +8 more
doaj +1 more source
A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models
Frontiers in Molecular Biosciences, 2022 Friedreich’s ataxia (FA) is an inherited multisystemic neuro- and cardio-degenerative disorder. Seventy-four clinical trials are listed for FA (including past and present), but none are considered FDA/EMA-approved therapy.
Rosella Abeti +7 more
doaj +1 more source
Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis
, 2022 Early lymphopenia is a known side effect of dimethyl fumarate, a disease-modifying therapy for MS. However, the long-term effects on immune response and the impact on lymphocyte counts when another disease-modifying treatment is introduced, remain ...
A. Mathias +11 more
core +1 more source
JID Innovations, 2021 Dimethyl fumarate (DMF) is an effective oral treatment for psoriasis administered in Europe for nearly 60 years. However, its potential has been limited by contact dermatitis that prohibits topical application.
Krzysztof Bojanowski +4 more
doaj +1 more source
Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
Dermatology Reports, 2021 Psoriasis is a chronic condition for which multiple therapies are currently available. In particular, in cases of moderate-severe psoriasis, traditional systemic drugs or the new biological drugs can be administered.
Martina Burlando +3 more
doaj +1 more source
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease [PDF]
, 2020 Background & Aims Alcohol-related liver disease (ALD) comprises different liver disorders which impose a health care issue. ALD and particularly alcoholic steatohepatitis, an acute inflammatory condition, cause a substantial morbidity and mortality ...
Sangineto, Moris +25 more
core +2 more sources
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method [PDF]
, 2023 Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience.
Kazuo Fujihara +23 more
core +2 more sources
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
Pharmaceuticals, 2020 COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and ...
Cara A. Timpani, Emma Rybalka
doaj +1 more source
Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi +8 more
wiley +1 more source